Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Allogene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Allogene Therapeutics's regulatory disclosures and financial reporting.
Allogene Therapeutics President and CEO Zachary Roberts reported equity awards rather than open-market trades. He received a grant of 476,190 stock options to buy common stock at an exercise price of $2.11 per share, expiring on July 1, 2036. Twenty-five percent of these options vest on July 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Roberts was also granted 134,530 Restricted Stock Units, each representing one share of common stock. These RSUs vest in four equal annual installments over the four-year period starting July 20, 2026, subject to his continued service. The filing shows compensation-related acquisitions, with no reported stock purchases or sales in the market.
Allogene Therapeutics director Joshua A. Kazam reported equity compensation activity. On June 18, 2026, he exercised 47,700 Restricted Stock Units (RSUs), which converted into the same number of common shares, bringing his direct common stock holdings to 398,463 shares after the transactions.
On the same date he received a new award of 95,400 RSUs under the company’s 2018 plan. Each RSU represents a contingent right to receive one share of Allogene common stock, or cash at the company’s discretion, and will vest in two equal semi-annual installments over one year, subject to continued service.
MESSEMER DEBORAH M. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Deborah M. Messemer received a grant of 95,400 restricted stock units (RSUs). The award carries no purchase price and gives her the contingent right to receive 95,400 shares of Allogene common stock if the units vest.
According to the terms, the RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to her continued service through each vesting date. Following this grant, she holds 95,400 RSUs directly.
Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.
Allogene Therapeutics director Vicki L. Sato received a grant of 95,400 Restricted Stock Units. These RSUs give her the right to receive an equal number of Allogene common shares at future vesting dates, without paying an exercise price.
The award will vest in two equal semi-annual installments over one year from the grant date, as long as she continues to provide service through each vesting date. This filing does not report any open-market purchases or sales, only a compensation-related equity grant.
WITTE OWEN N. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Owen N. Witte received a grant of 95,400 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date.
Witte has elected to defer receipt of the underlying common shares until the earlier of 30 days after his separation from continuous service with the company or a change in control of Allogene, in line with the company’s Non-Employee Director Compensation Policy.
Humer Franz B reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics director Franz B. Humer received an equity grant of 95,400 restricted stock units. Each RSU represents a contingent right to one share of Allogene common stock. The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to continued service.
The director has elected to defer receiving the common shares until the earlier of 30 days after leaving continuous service with the company or a change in control of Allogene.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Allogene Therapeutics, Inc. director Elizabeth A. Barrett received a grant of 95,400 Restricted Stock Units. Each RSU represents a contingent right to one share of Allogene common stock.
The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to her continued service. Barrett has elected to defer delivery of the underlying shares until the earlier of 30 days after leaving continuous service or a change in control of the company.
Allogene Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders and related corporate actions. Stockholders elected three Class II directors to serve until the 2029 annual meeting and approved, on an advisory basis, the compensation of named executive officers and an annual say-on-pay vote.
Stockholders also approved an amendment to increase authorized common shares from 400,000,000 to 800,000,000, which became effective on June 18, 2026. They ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026. Separately, the company filed a prospectus supplement covering sales of common stock with an aggregate offering price of up to $135.0 million under an existing Sales Agreement with TD Securities (U.S.A.) LLC.
Allogene Therapeutics filed a prospectus supplement to sell up to $135,000,000 of common stock through an at‑the‑market program with TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time at market prices and TD Cowen’s commission is up to 3.0% of gross proceeds. The supplement references a last reported sale price of $2.00 per share on June 18, 2026 and states proceeds will be used for general corporate purposes, including clinical trials, R&D, G&A and capital expenditures. The company also amended its charter to increase authorized common shares to 800,000,000.